---
title: Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours
nct_id: NCT00991601
overall_status: SUSPENDED
phase: NA
sponsor: Herlev Hospital
study_type: INTERVENTIONAL
primary_condition: Tumors in Liver
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00991601.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00991601"
ct_last_update_post_date: 2010-10-13
last_seen_at: "2026-05-12T06:29:16.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours

**NCT ID:** [NCT00991601](https://clinicaltrials.gov/study/NCT00991601)

## Key Facts

- **Status:** SUSPENDED
- **Why Stopped:** New ultra sound technology have made this present study design less relevant and force us to change the design of the study.
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 150
- **Lead Sponsor:** Herlev Hospital
- **Conditions:** Tumors in Liver, Tumors in Pancreas
- **Start Date:** 2009-07
- **Completion Date:** 2011-12
- **CT.gov Last Update:** 2010-10-13

## Brief Summary

Patients with tumors in liver or pancreas are randomized to ultrasound (UL)-guided FNAC biopsies with guidance method or UL-guided FNAC biopsies with free-hand method.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* adult over 18 years
* tumors in liver and/or pancreas

Exclusion Criteria:

* low coagulation factors
* mentally ill patients.
```

## Arms

- **biopsy arm** (EXPERIMENTAL) — patients with tumors in liver and/or pancreas

## Interventions

- **FNAC (fine needle aspiration cytology)** (PROCEDURE) — UL guided biopsy

## Primary Outcomes

- **quality of obtained biopsy** _(time frame: one year)_

## Secondary Outcomes

- **patients pain and discomfort at procedure** _(time frame: immediately)_

## Locations (1)

- Herlev Hospital, Dk-2730, Herlev, Herlev, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.herlev hospital|dk-2730, herlev|herlev|denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00991601.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00991601*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*